Single-Dose Hybrid Hyaluronic Acid and Sodium Chondroitin with Rehabilitation for Sports Adults with Knee Osteoarthritis

Launched by UNIVERSITY OF PALERMO · Mar 16, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for adults aged 18 to 50 who have moderate to severe knee osteoarthritis, a condition that causes pain and stiffness in the knee joint. The study will look at whether a single injection of a special combination of hyaluronic acid and sodium chondroitin, along with rehabilitation exercises, can help improve pain relief, physical function, and overall quality of life compared to rehabilitation alone. Participants will be divided into two groups—one group will receive the injection and rehabilitation, while the other group will only receive rehabilitation. The effectiveness of the treatments will be measured through strength and endurance tests.

To be eligible for this study, participants must have a confirmed diagnosis of knee osteoarthritis that has lasted for at least six months and experience ongoing pain that affects their ability to perform physical activities. They should not have any other serious joint diseases, recent treatments that could interfere with the study, or certain health conditions. This trial is currently not recruiting participants, but it offers a potential new approach for managing knee pain in active adults who have not found relief with other treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged between 18 and 50 years.
• • Radiologically confirmed diagnosis of knee osteoarthritis (Kellgren-Lawrence grade ≤3), present for at least 6 months.
• • Persistent moderate to severe pain due to osteoarthritis, interfering with physical performance.
• • Documented reduction in sports performance (use appropriate scales or tests to validate this).
• • Lack of response to pharmacological or other conservative treatments.
• • Willingness to provide written informed consent for participation.
• Exclusion Criteria:
• • Coexisting rheumatic diseases.
• • History of intra-articular viscosupplementation in the target knee within the previous 6 months.
• • Presence of significant venous or lymphatic stasis.
• • Body Mass Index (BMI) ≥ 30 kg/m².
• • Use of systemic or intra-articular corticosteroids in the target knee within the last 3 months.
• • Chronic use of topical/systemic analgesics, NSAIDs, or narcotics.
• • History of alcohol or drug abuse.
• • Allergy or hypersensitivity to hyaluronic acid or any of its components.
• • Pregnant or breastfeeding women, or those not using adequate contraception.